المؤلفون: Li M; Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.; College of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, China., Ge Z; Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China., Zhang B; College of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, China., Sun L; Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China., Wang Z; Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China., Zou T; Department of Pharmacy, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, Guizhou, China., Chen Q; Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China. chenqi@gz5055.com.; College of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, China. chenqi@gz5055.com.

المصدر: Archives of osteoporosis [Arch Osteoporos] 2024 Sep 23; Vol. 19 (1), pp. 89. Date of Electronic Publication: 2024 Sep 23.

نوع المنشور: Journal Article; Meta-Analysis; Systematic Review

بيانات الدورية: Publisher: Springer Country of Publication: England NLM ID: 101318988 Publication Model: Electronic Cited Medium: Internet ISSN: 1862-3514 (Electronic) NLM ISO Abbreviation: Arch Osteoporos Subsets: MEDLINE

مواضيع طبية MeSH: Teriparatide*/therapeutic use , Teriparatide*/adverse effects , Denosumab*/therapeutic use , Denosumab*/adverse effects , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/adverse effects , Randomized Controlled Trials as Topic* , Osteoporosis*/drug therapy , Diphosphonates*/therapeutic use , Diphosphonates*/adverse effects , Bone Density*/drug effects, Humans ; Osteoporotic Fractures/prevention & control ; Treatment Outcome

المؤلفون: Bala A; Endocrinology and Diabetes Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India., Dayal D; Endocrinology and Diabetes Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.

المصدر: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Sep 16; Vol. 109 (10), pp. e1971-e1972.

نوع المنشور: Letter; Editorial; Comment

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE

مواضيع طبية MeSH: Osteogenesis Imperfecta*/drug therapy , Denosumab*/therapeutic use , Denosumab*/adverse effects , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/adverse effects, Humans ; Child ; Prospective Studies ; Treatment Outcome

المؤلفون: Grassi G; Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy., Ghielmetti A; Department of Clinical Sciences and Community Health, University of Milan, 20100 Milan, Italy., Zampogna M; Department of Clinical Sciences and Community Health, University of Milan, 20100 Milan, Italy., Chiodini I; Department of Medical Biotechnology and Translational Medicine, University of Milan, 20100 Milan, Italy.; Unit of Endocrinology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy., Arosio M; Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.; Department of Clinical Sciences and Community Health, University of Milan, 20100 Milan, Italy., Mantovani G; Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.; Department of Clinical Sciences and Community Health, University of Milan, 20100 Milan, Italy., Eller-Vainicher C; Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

المصدر: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Sep 16; Vol. 109 (10), pp. e1817-e1826.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE

مواضيع طبية MeSH: Zoledronic Acid*/administration & dosage , Zoledronic Acid*/therapeutic use , Denosumab*/administration & dosage , Denosumab*/therapeutic use , Bone Density Conservation Agents*/administration & dosage , Bone Density Conservation Agents*/therapeutic use , Bone Density*/drug effects, Humans ; Female ; Aged ; Retrospective Studies ; Middle Aged ; Aged, 80 and over ; Drug Administration Schedule ; Spinal Fractures/prevention & control ; Spinal Fractures/epidemiology ; Treatment Outcome ; Diphosphonates/administration & dosage ; Diphosphonates/therapeutic use ; Withholding Treatment/statistics & numerical data ; Male ; Collagen Type I/blood ; Peptides

المؤلفون: Yang J; Department of Orthopedics, Jincheng General Hospital, Jincheng, China., Guo X; Department of Orthopedics, Jincheng General Hospital, Jincheng, China., Cui Z; Department of Orthopedics, Jincheng General Hospital, Jincheng, China., Guo H; Department of Orthopedics, Jincheng General Hospital, Jincheng, China., Dong JN; Department of Gynecology, Gaoping People's Hospital, Jincheng, China.

المصدر: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Sep 02; Vol. 15, pp. 1431676. Date of Electronic Publication: 2024 Sep 02 (Print Publication: 2024).

نوع المنشور: Systematic Review; Meta-Analysis; Journal Article; Comparative Study

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE

مواضيع طبية MeSH: Denosumab*/therapeutic use , Denosumab*/administration & dosage , Osteoporosis, Postmenopausal*/drug therapy , Teriparatide*/administration & dosage , Teriparatide*/therapeutic use , Teriparatide*/adverse effects , Bone Density Conservation Agents*/administration & dosage , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/adverse effects , Diphosphonates*/administration & dosage , Diphosphonates*/therapeutic use, Humans ; Female ; Administration, Oral ; Bone Density/drug effects ; Treatment Outcome

المؤلفون: Anastasilakis AD; Department of Endocrinology, 424 Military General Hospital, 56429, Thessaloniki, Greece., Polyzos SA; First Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece., Makras P; Department of Endocrinology and Diabetes and Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 15561, Athens, Greece., Savvidis M; 1st Department of Orthopedics, 424 Military General Hospital, 56429, Thessaloniki, Greece., Mantzoros CS; Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Harvard Medical School, Boston VA Healthcare System and Beth Israel Deaconess Medical Center, 02215, Boston, MA, United States.

المصدر: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2024 Sep 02; Vol. 39 (9), pp. 1306-1314.

نوع المنشور: Journal Article; Comparative Study; Clinical Trial

بيانات الدورية: Publisher: American Society for Bone and Mineral Research Country of Publication: England NLM ID: 8610640 Publication Model: Print Cited Medium: Internet ISSN: 1523-4681 (Electronic) Linking ISSN: 08840431 NLM ISO Abbreviation: J Bone Miner Res Subsets: MEDLINE

مواضيع طبية MeSH: Teriparatide*/pharmacology , Teriparatide*/therapeutic use , Denosumab*/therapeutic use , Denosumab*/pharmacology , Activins*/blood , Activins*/metabolism , Osteoporosis, Postmenopausal*/drug therapy , Osteoporosis, Postmenopausal*/blood , Osteoporosis, Postmenopausal*/metabolism , Follistatin*/blood, Humans ; Female ; Aged ; Middle Aged

المؤلفون: Diab DL; College of Medicine, Cincinnati VA Medical Center, Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati, Cincinnati, OH, USA., Watts NB; Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, USA.

المصدر: Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Sep; Vol. 23 (9), pp. 1069-1077. Date of Electronic Publication: 2024 Sep 11.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE

مواضيع طبية MeSH: Denosumab*/adverse effects , Denosumab*/administration & dosage , Osteoporosis*/chemically induced , Osteoporosis*/drug therapy , Bone Density Conservation Agents*/adverse effects , Bone Density Conservation Agents*/administration & dosage, Humans ; Female ; Bone Density/drug effects ; Male ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/pharmacology ; RANK Ligand/adverse effects ; RANK Ligand/antagonists & inhibitors ; RANK Ligand/administration & dosage ; Animals ; Diphosphonates/adverse effects ; Diphosphonates/administration & dosage ; Fractures, Bone/chemically induced ; Fractures, Bone/prevention & control

المؤلفون: Kumar S; Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, Australia.; Faculty of Medicine & Health, University of Sydney, Sydney, Australia.; Department of Diabetes & Endocrinology, Royal North Shore Hospital, Sydney, Australia., Gild ML; Faculty of Medicine & Health, University of Sydney, Sydney, Australia.; Department of Diabetes & Endocrinology, Royal North Shore Hospital, Sydney, Australia., McDonald MM; Faculty of Medicine, University of New South Wales, Sydney, Australia.; Bone Biology Program, Garvan Institute of Medical Research, Sydney, Australia., Kim AS; Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, Australia.; Faculty of Medicine, University of New South Wales, Sydney, Australia.; Bone Biology Program, Garvan Institute of Medical Research, Sydney, Australia., Clifton-Bligh RJ; Faculty of Medicine & Health, University of Sydney, Sydney, Australia.; Department of Diabetes & Endocrinology, Royal North Shore Hospital, Sydney, Australia., Girgis CM; Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, Australia. Christian.girgis@sydney.edu.au.; Faculty of Medicine & Health, University of Sydney, Sydney, Australia. Christian.girgis@sydney.edu.au.

المصدر: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2024 Sep; Vol. 35 (9), pp. 1669-1675. Date of Electronic Publication: 2024 Jun 05.

نوع المنشور: Journal Article; Case Reports

بيانات الدورية: Publisher: Springer International Country of Publication: England NLM ID: 9100105 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2965 (Electronic) Linking ISSN: 0937941X NLM ISO Abbreviation: Osteoporos Int Subsets: MEDLINE

مواضيع طبية MeSH: Denosumab*/therapeutic use , Denosumab*/administration & dosage , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/administration & dosage , Bone Density*/drug effects , Osteoporotic Fractures*/prevention & control , Osteoporotic Fractures*/physiopathology , Drug Administration Schedule* , Osteoporosis*/drug therapy , Osteoporosis*/physiopathology , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/therapeutic use, Humans ; Female ; Aged ; Drug Therapy, Combination ; Male ; Bone Remodeling/drug effects ; Middle Aged ; Lumbar Vertebrae/physiopathology

المؤلفون: Latorre CG; Faculty of Dentistry, Universidad Andres Bello, Viña del Mar, Chile., Atalah CN; Faculty of Dentistry, Universidad Andres Bello, Viña del Mar, Chile., Marshall Baburizza M; Faculty of Dentistry, Universidad Andres Bello, Viña del Mar, Chile. maureen.marshall@unab.cl.; Oral Pathology and Oral Medicine Unit, Faculty of Dentistry, Universidad Andres Bello, Quillota 980, Viña del Mar, Chile. maureen.marshall@unab.cl.

المصدر: Oral and maxillofacial surgery [Oral Maxillofac Surg] 2024 Sep; Vol. 28 (3), pp. 1029-1045. Date of Electronic Publication: 2024 Mar 28.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101319632 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-1569 (Electronic) Linking ISSN: 18651550 NLM ISO Abbreviation: Oral Maxillofac Surg Subsets: MEDLINE

مواضيع طبية MeSH: Denosumab*/therapeutic use , Denosumab*/adverse effects , Granuloma, Giant Cell*/drug therapy , Jaw Diseases*/drug therapy , Jaw Diseases*/chemically induced , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/adverse effects, Humans ; Child ; Adult ; Treatment Outcome

المؤلفون: Tanaka Y; First Department of Internal Medicine, Faculty of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan., Mizutani H; Post Marketing Study Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Fujii K; Post Marketing Study Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Okubo N; Biostatistics & Data Management Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

المصدر: Modern rheumatology [Mod Rheumatol] 2024 Aug 20; Vol. 34 (5), pp. 927-935.

نوع المنشور: Journal Article; Observational Study

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 100959226 Publication Model: Print Cited Medium: Internet ISSN: 1439-7609 (Electronic) Linking ISSN: 14397595 NLM ISO Abbreviation: Mod Rheumatol Subsets: MEDLINE

مواضيع طبية MeSH: Arthritis, Rheumatoid*/drug therapy , Denosumab*/adverse effects , Denosumab*/therapeutic use , Product Surveillance, Postmarketing* , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/adverse effects, Humans ; Female ; Male ; Middle Aged ; Aged ; Japan/epidemiology ; Treatment Outcome ; Prospective Studies ; Disease Progression ; Adult ; Antirheumatic Agents/therapeutic use ; Antirheumatic Agents/adverse effects ; East Asian People

المؤلفون: Beale F; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom., Gkiourtzis N; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom.; 4th Pediatric Department AUTH, 'Papageorgiou' General Hospital, Thessaloniki, Greece., Koneru S; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom., O'Brien C; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom., Lalayiannis AD; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom. alex.lalayiannis@nhs.net.

المصدر: Pediatric nephrology (Berlin, Germany) [Pediatr Nephrol] 2024 Aug; Vol. 39 (8), pp. 2355-2358. Date of Electronic Publication: 2024 Jan 26.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 8708728 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-198X (Electronic) Linking ISSN: 0931041X NLM ISO Abbreviation: Pediatr Nephrol Subsets: MEDLINE

مواضيع طبية MeSH: Hypercalcemia*/etiology , Hypercalcemia*/drug therapy , Hypercalcemia*/diagnosis , Kidney Transplantation*/adverse effects , Denosumab*/adverse effects , Denosumab*/therapeutic use , Pneumonia, Pneumocystis*/diagnosis , Pneumonia, Pneumocystis*/etiology , Pneumocystis carinii*, Humans ; Male ; Renal Insufficiency, Chronic/complications ; Bone Density Conservation Agents/adverse effects ; Bone Density Conservation Agents/therapeutic use ; Adolescent ; Female ; Child